Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Apollomics Inc. (Nasdaq: APLM) announced it entered into a $2.0 million unsecured convertible promissory note with its Chairman and CEO, Mr. Hung-Wen (Howard) Chen, dated March 30, 2026. The note provides proceeds intended for working capital to support clinical development programs and general corporate operations.
The note carries 0% interest and automatically converts into equity securities upon the closing of a subsequent equity financing with aggregate gross proceeds of at least $10.0 million. The conversion price is set at a 20% discount to the lowest per-share price issued in that financing.
The related-party terms were reviewed and approved by the company’s independent audit committee and board, with Mr. Chen abstaining.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026